by Gordon Hensley | Feb 19, 2026 | Business, health care, Pharmaceutical |
Congratulations to the team at Altesa BioSciences and CEO Dr. Brett Giroir for their collective success achieving an oversubscribed $75 million Series B round of financing as the Atlanta-based biotech continues its mission to transform the treatment of COPD, asthma...
by Gordon Hensley | Feb 10, 2026 | advocacy, Business, Communications, health care, lobbying, Media Relations |
I didn’t see firsthand how the K Street lobbying scene worked until the tail-end of my 30s and a little voice in my head said it was time to become an adult — or at least more of an adult. I was having the time of my life going through a revolving door I...
by Gordon Hensley | Jun 12, 2023 | CMS, Communications, COVID, FDA, health care, HHS |
When Covid began to run roughshod over the U.S in mid-2020 I had an opportunity to work as a “senior advisor” at the U.S. Department of Health and Human Services (HHS). I spent much of my time working with Covid “testing czar” Brett Giroir and...
by Gordon Hensley | Feb 23, 2021 | advocacy, Business, Campaign 2020, CDC, CMS, COVID, health care, HHS, Media Relations, Pharmaceutical, SNF, state government, Trump
Kudos to CBS Face the Nation moderator Margaret Brennan for her excellent interview of former Trump Administration Deputy National Security Advisor, Matthew F. Pottinger, surrounding several facets of the Trump Administration’s COVID-19 response. The discussion...
by Gordon Hensley | Oct 28, 2019 | advocacy, Business, GOP Politics, health care, Health Reform
As a Republican and admitted ideologue when it comes to assigning blame to “big government” and “regulatory overreach” for many of the nation’s ills, Axios points out today that, “Private equity firms don’t just own physician...
by Gordon Hensley | Jun 18, 2019 | advocacy, Business, CMS, health care, Medicaid funding, Pharmaceutical, state government
With pharmacy benefit managers (PBMs) under a cloud of their own making due to a business model wholly dependent upon opaque, non-transparent drug pricing practices, the Centers for Medicare and Medicaid Services (CMS) recently prohibited yet another controversial PBM...
